Skip to content

Clinical Observation of Jiaweizaoqi Decoction in the Treatment of Insulin Resistance in Polycystic Ovary Syndrome

Clinical Observation of Jiaweizaoqi Decoction in the Treatment of Polycystic Ovary Syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000385
Enrollment
Unknown
Registered
2025-02-21
Start date
2024-04-13
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovarian syndrome

Interventions

Metformin group:Metformin per os
Jiaweizaoqi Decoction group:Jiaweizaoqi Decoction PER OS

Sponsors

Shanghai No.7 People ' s Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 35 Years

Inclusion criteria

Inclusion criteria: ( 1 ) 20-35 years old ; ( 2 ) Consistent with the diagnostic criteria for PCOS ; ( 3 ) Consistent with the diagnostic criteria for IR ; ( 4 ) Patients who meet the dialectical criteria of kidney deficiency and phlegm stasis syndrome in traditional Chinese medicine ; ( 5 ) Voluntary subjects and signed informed consent regular follow-up.

Exclusion criteria

Exclusion criteria: ( 1 ) Patients with hyperandrogenism caused by other causes such as Cushing 's syndrome non-classical congenital adrenal hyperplasia ovarian or adrenal androgen-secreting tumors and other diseases that cause ovulation dysfunction such as pituitary or hypothalamic amenorrhea hyperprolactinemia premature ovarian failure etc. ( 2 ) excluding organic diseases or other endocrine diseases ; ( 3 ) Complicated with severe liver and kidney cardiovascular and cerebrovascular diseases and hematopoietic system dysfunction and mental patients ; ( 4 ) Patients who had taken hormonal drugs such as contraceptives glucocorticoids or participated in other clinical trials in the past 3 months ; ( 5 ) Those who do not meet the inclusion criteria or incomplete data affect the judgment.

Design outcomes

Primary

MeasureTime frame
Menstrual status score;ovulation rate;

Secondary

MeasureTime frame
BMI;IGF-1;WHR;chinese medicine syndrome scores;HOMA-IR;sexual hormone;IL-1ß;leptin;

Countries

China

Contacts

Public ContactHong Tang

Shanghai No.7 People ' s Hospital

elaine_tanghong@126.com13585976653

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026